PTC Therapeutics IncPTCT
Price$64.13

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $1B+25.0% YoYTTM through 30 Jun 2026
Net Income -$38.4MTTM through 30 Jun 2026
Free Cash Flow -$39.8MTTM through 30 Jun 2026

Margins

Current
Gross Margin97.3%
EBITDA Margin17.9%
Operating Margin49.5%
Net Margin-3.8%

Returns

-332.5%ROE
23.5%ROA
6.1%ROIC

Balance Sheet Health

Debt / Equity-1.40x
Current Ratio3.39x
Net Debt-$1.7Bnet cash position
Cash & Equivalents$1B

Quality Metrics

Altman Z-Score0.84
Piotroski F-Score4 / 9
FCF Margin-3.9%
Rule of 4020.5
Earnings-Beat Rate75.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $1.7B
Diluted EPS-$0.61TTM
'19'20'21'22'23'24'25
FY2025: $7.73

Dividend

No dividend

Capital Allocation

R&D Spend$433.3M
Capex Intensity0.9%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.